AlloSCT for Blood Disorders
Phase 2
20
about 6.8 years
0.00273790700698851–30
1 site in NY
What this study is about
This trial is testing a new way to prepare stem cells before an allogeneic stem cell transplant (AlloSCT) for people with blood disorders. The treatment involves removing certain immune cells from the stem cells using alpha/beta depletion. This may help improve outcomes for patients undergoing AlloSCT.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take alpha beta depletion
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: incidence of adverse events related to administration of α/β CD3+/CD19+ cell depleted stem cells
Oncology